Weight loss drug maker sinks 25% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Weight loss drug maker sinks 25% after new safety data spooks investors
Overview
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Source
Originally published at www.cnbc.com.
Related Articles
- 51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey
- A massive 16% market swing just rocked South Korea over 24 hours. The retail ‘ants’ holding the wheel are driving dangerously.
- I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
